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Abstract 
Toxins and venom components that target voltage-gated sodium (NaV) channels have evolved 
numerous times due to the importance of this class of ion channels in the normal 
physiological function of peripheral and central neurons as well as cardiac and skeletal 
muscle. NaV channel activators in particular have been isolated from the venom of spiders, 
wasps, snakes, scorpions, cone snails and sea anemone and are also produced by plants, 
bacteria and algae. These compounds have provided key insight into the molecular structure, 
function and pathophysiological roles of NaV channels and are important tools due to their at 
times exquisite subtype-selectivity. We review the pharmacology of NaV channel activators 
with particular emphasis on mammalian isoforms and discuss putative applications for these 
compounds. 
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 1 
Key Words 1 
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 3 
1. Introduction 4 
Voltage-gated sodium (NaV) channels are key transmembrane proteins that permit 5 
influx of Na+ in excitable and non-excitable cells where they contribute to setting the 6 
membrane potential, action potential initiation and propagation, as well as cell 7 
motility and proliferation. While NaV channels can be found in many tissues and cell 8 
types, they are particularly important for the function of central and peripheral 9 
neurons as well as skeletal and cardiac muscle. Nine voltage-sensing pore forming α 10 
subunit isoforms have been described in humans (NaV1.1, NaV1.2, NaV1.3, NaV1.4, 11 
NaV1.5, NaV1.6, NaV1.7, NaV1.8, and NaV1.9; encoded by the genes SCN1A, 12 
SCN2A, SCN3A, SCN4A, SCN5A, SCN8A, SCN9A, SCN10A and SCN11A, 13 
respectively), each with distinct expression profiles. The contribution of each of these 14 
isoforms to tissue- and disease-specific physiology and pathology makes NaV 15 
channels important therapeutic targets for treatment of a range of diseases, including 16 
epilepsy, pain, myotonias, cardiac arrhythmias and insufficiencies as well as cancer 17 
(Luiz and Wood, 2016; Mantegazza et al., 2010; Novak et al., 2015; Zaklyazminskaya 18 
and Dzemeshkevich, 2016). However, most drug discovery efforts to date have been 19 
directed at the development of subtype-selective NaV channel inhibitors. 20 
The endogenous “activator” of NaV channels is membrane voltage, more specifically 21 
the distribution of charge across membrane bilayers which in turn affects the position 22 
of charged transmembrane segments, leading to opening or closing of the central, 23 
Na+-permeable pore. Many toxins and venom components have evolved to hijack this 24 
activation mechanism by stabilising the activated conformation of the channel via 25 
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 2 
interactions with extracellular or transmembrane domains. These compounds thus act 1 
as net channel activators, although the specific effects on the electrophysiological 2 
properties of the channel can vary significantly.  3 
While they have been overlooked, in relative terms, for their clinical utility, NaV 4 
channel activators not only have applications in the treatment of disease, they are also 5 
indispensable tool compounds and have provided key insights into the molecular 6 
mechanisms governing function of this important class of ion channels. Moreover, 7 
plant-derived or synthetic NaV channel activators such as pyrethrins are one of the 8 
most commonly used classes of insecticides, with uncontrolled Na+ influx leading to 9 
rapid spastic paralysis. In light of emerging resistance to these molecules (Silva et al., 10 
2014), novel classes of NaV channel activators may play important roles in the control 11 
of agricultural pests and vectors of insect-borne disease. Venom-derived peptides in 12 
particular may confer benefits as more environmentally friendly compounds that are 13 
less likely to accumulate and cause unwanted toxic effects on humans, wildlife, and 14 
beneficial insects (Li et al., 2017). 15 
 16 
NaV channel activators have also provided key insights into the molecular 17 
mechanisms underpinning channel activation and inactivation – key processes that are 18 
essential for normal cellular function. Future insights into the molecular and structural 19 
components involved in channel gating will undoubtedly facilitate the rational design 20 
of highly subtype-selective NaV channel modulators with therapeutic potential. 21 
 22 
Lastly, NaV channel activators also represent important tool compounds that permit 23 
the dissection of the physiological and pathological roles of individual NaV channel 24 
isoforms. They have in addition been instrumental for the development of high-25 
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 3 
throughput screening assays leading to the identification of subtype-selective NaV 1 
channel inhibitors, as control of membrane potential can be difficult to achieve in 2 
traditional drug discovery assays (Vetter et al., 2012a). 3 
 4 
This review will summarise effects of various classes of NaV channel activators, 5 
including peptide toxins from spider, wasp, snake, scorpion, cone snail and sea 6 
anemone venoms as well as alkaloids and polyethers derived from bacteria and 7 
dinoflagellates, with particular emphasis on pharmacology at mammalian NaV 8 
channels. 9 
 10 
2. Physiology of NaV channels 11 
NaV channels are a group of sodium (Na+) selective ion channels that are normally 12 
activated by voltage changes across cellular membranes, leading to channel opening 13 
and a subsequent transmembrane influx of Na+ ions along their electrochemical 14 
gradient into the cell (Chandler and Meves, 1965; Hille, 1972; Hodgkin and Huxley, 15 
1952a, b, c). NaV channels are essential for the initiation and propagation of action 16 
potentials in electrically excitable cells like nerves and muscle fibres. They are 17 
responsible for the initial depolarization of the membrane and thus crucial for the fast 18 
electrical signalling that is necessary to propagate vital information over long 19 
distances in animals (Hodgkin and Huxley, 1952a, b, c, d). 20 
The ion conducting α-subunits can form multi-protein signalling complexes by 21 
coupling to one or two cell type specific auxiliary proteins, such as the β subunits β1 - 22 
β4 (encoded by the genes SCN1B - SCN4B), which modulate NaV channel biophysics 23 
and trafficking (Meadows and Isom, 2005; O'Malley and Isom, 2015).  24 
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 4 
The individual NaV channel subtypes are defined by the nine different α subunits that 1 
also contain many binding sites for toxins and other modulating compounds. Seven 2 
NaV channels NaV1.1, NaV1.2, NaV1.3, NaV1.6, NaV1.7, NaV1.8, and NaV1.9 play 3 
major roles in electrogenesis in neurons. The subtypes that are expressed at 4 
considerable levels in the central nervous system (CNS) include NaV1.1, NaV1.2, 5 
NaV1.3 and NaV1.6, where they can only be targeted by compounds that cross the 6 
blood-brain barrier. Widely expressed in the peripheral nervous system (PNS) are 7 
NaV1.1, NaV1.6, NaV1.7, NaV1.8, and NaV1.9. Impulse electrogenesis and conduction 8 
in skeletal muscle cells and in cardiomyocytes is carried out by NaV1.4 and NaV1.5, 9 
respectively (Catterall et al., 2005; Goldin, 1999). Additionally, multiple NaV channel 10 
subtypes are expressed in many non-excitable cell types like astrocytes, microglia, 11 
macrophages, and cancer cells where they play a role in e.g. the release of bioactive 12 
molecules or regulating motility, Na+/K+-ATPase activity, phagocytosis and 13 
metastatic activity (Black and Waxman, 2013; de Lera Ruiz and Kraus, 2015).  14 
 15 
Due to the important role of NaV channels and their wide tissue distribution, it is not 16 
surprising that NaV channel dysfunction plays an important role in numerous severe 17 
pathological conditions including epilepsy (Heron et al., 2002; Liao et al., 2010; 18 
Sugawara et al., 2001), migraine (Dichgans et al., 2005), ataxia (Liao et al., 2010; 19 
Trudeau et al., 2006), multiple sclerosis (Waxman, 2006), various painful conditions 20 
(Dib-Hajj et al., 2013; Faber et al., 2012a; Faber et al., 2012b; Fertleman et al., 2006; 21 
Vetter et al., 2017; Yang et al., 2004), the inability to experience pain (Ahmad et al., 22 
2007; Cox et al., 2006), heart disorders (Medeiros-Domingo et al., 2007; Song and 23 
Shou, 2012; Tarradas et al., 2013) and neuromuscular diseases (Cannon, 2010; Jurkat-24 
Rott et al., 2010). These conditions are often caused by inherited or spontaneous 25 
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 5 
mutations, but can also be the result of injuries, adverse drug reactions or 1 
intoxications that result in hypo- and hyper-excitable phenotypes (Dib-Hajj and 2 
Waxman, 2010; Wood et al., 2004). The pharmacological modulation of any NaV 3 
channel in the CNS, in the heart or in muscle cells has the potential risk of life-4 
threatening side effects like seizures, cardiac arrhythmia or muscle paralysis resulting 5 
in respiratory arrest. For this reason, high potency and subtype selectivity is a much 6 
sought after characteristic in the development of pharmaceutical drugs. Both are 7 
common features of many natural toxins and venom derived peptides as a result of 8 
ongoing evolutionary specialisation and optimization. 9 
 10 
The Nax channel (also known as NaG or NaV2.1, in humans encoded by the gene 11 
SCN7A) also belongs to the family of the voltage-gated sodium channels, even 12 
though it is not activated by changes in membrane potential. Instead it is activated by 13 
an increased extracellular Na+ concentration and is involved in sodium level sensing 14 
in the central nervous system, in controlling salt intake behaviour as well as in 15 
regulating epithelial sodium homeostasis (Hiyama et al., 2002; Watanabe et al., 2000; 16 
Xu et al., 2015). We use the term “voltage-gated sodium (NaV) channel” here to mean 17 
the family of voltage activated NaV1.X channels. 18 
 19 
 20 
3. Structure of NaV channels 21 
3.1. Structure and function of α-subunits 22 
Structural information on NaV channels has for a long time lagged behind functional 23 
and pharmacological characterisation. The first insights into the principal NaV channel 24 
structure was obtained from studies with radiolabelled toxin-derivatives such as 25 
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 6 
modified [3H]saxitoxin and a [125I]β-scorpion toxin that covalently bind to their 1 
receptor site. These toxins helped to identify distinct binding sites as well as the 2 
existence of one larger alpha subunit (260 kDa) and several smaller beta subunits 3 
(30−40 kDa) (Beneski and Catterall, 1980; Hartshorne et al., 1982). The same toxins 4 
also enabled the purification of a NaV channel from the electric organ of an eel and 5 
allowed for cloning and sequence analysis of the cDNA, which revealed the amino 6 
acid sequence and thus the first primary structure of a NaV channel (Noda et al., 7 
1984). This started an era of educated guesswork on how the human NaV channel 8 
structure might change during gating, and how toxins interact with the channel, that 9 
continues to date. Although we are still lacking three-dimensional high-resolution 10 
data from mammalian channels, many features can be deduced from insights from 11 
site-directed mutagenesis studies, elegant functional and pharmacological studies as 12 
well as crystal structures of the closely related bacterial channels and the cryo-EM 13 
structure of a putative NaV channel from the American cockroach (Shen et al., 2017).  14 
 15 
We now know that all human NaV channel α subunits likely can form functional 16 
monomers that consist of one long polypeptide chain, which folds into four 17 
homologous but markedly different repeat domains (DI - DIV), linked by three 18 
intracellular loops, and congregate to a pseudo-tetrameric structure (Vetter et al., 19 
2017). Major structural differences between the nine human NaV channel α-subunits 20 
NaV1.1 – NaV1.9 are unlikely, as indicated by the high sequence homology between 21 
them. In contrast, the much simpler prokaryotic NaV channels, which have been 22 
recently used to determine NaV channel crystal structures, are homo-tetramers, i.e. 23 
formed by four identical and separate subunits, and thus more closely resemble the 24 
structural arrangement of the mammalian KV channels. 25 
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 1 
 2 
All NaV channels have similar functional characteristics and a common overall 3 
structure, indicated by the high level of sequence identity with about 50-90% identical 4 
amino acids between any two isoforms (Vetter et al., 2017). However, the 5 
pharmacological and kinetic properties as well as the voltage dependence of each 6 
voltage-gated sodium channels isoform are different and contribute to their distinct 7 
functional physiological and pharmacological roles (Catterall et al., 2005). 8 
 9 
The characteristic features of voltage-gated sodium channels are fast gating (i.e. 10 
channel opening and closing) with voltage-dependent activation, rapid inactivation 11 
and selective sodium ion conductance (Hodgkin and Huxley, 1952d). The channels’ 12 
voltage sensors move in response to the cellular membrane potential changes and thus 13 
determine the state in which the channels reside with the highest probability. NaV 14 
channels are closed at resting membrane potentials and require membrane 15 
depolarization to be activated. Activation of the channel leads to a fast opening of the 16 
pore domain due to a conformational change, resulting in selective Na+ ion influx into 17 
the cell and further membrane depolarization, thus contributing to the rapid upstroke 18 
of the action potential in excitable cells. The subsequent fast inactivation leads to a 19 
non-conducting channel state within milliseconds of opening (Catterall, 2012). 20 
NaV1.9 is an exception, taking longer  (>100 milliseconds) to inactivate than the other 21 
NaV subtypes (Dib-Hajj et al., 2015). A special form of inactivation is the slow 22 
channel inactivation that recovers only very slowly and can occur during repetitive 23 
neuronal firing, when membranes around NaV channels are depolarized for long 24 
periods (seconds) (Catterall, 2014). 25 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 8 
 1 
Each of the four homologous domains DI - DIV of human NaV channels contains six 2 
α-helical transmembrane segments (S1 - S6) and is divided into two functional 3 
domains, a pore domain (PD) and a voltage-sensing domain (VSD) (Figure 1). The 4 
ion-conducting pore of the channel is formed by the four assembled PDs of DI - DIV, 5 
which are each shaped by segments S5 and S6 plus their extracellular linker. These 6 
four linkers each contain a conserved pore loop (P-loop) that dips halfway back into 7 
the membrane between S5 and S6, where they tightly associate with each other. This 8 
creates a narrow Na+ selective filter formed by the amino acids DEKA and EEDD at 9 
the extracellular end of the pore. The pore region presents toxin binding sites on the 10 
external opening, close to the selectivity filter (for pore blockers like tetrodotoxin and 11 
the µ-conotoxins) as well as inside the pore (for gating modifiers like veratridine) (de 12 
Lera Ruiz and Kraus, 2015). 13 
The four functional and structural distinct VSDs are each shaped by the segments S1 14 
– S4 (Catterall, 2000; Guy and Seetharamulu, 1986) and linked to the PD via the S4 – 15 
S5 linker. The S4 segments function as voltage sensors of the channel as they carry 16 
several highly conserved positively charged arginine and lysine residues (gating 17 
charges) that are forced to move across the cell membrane upon changes in the 18 
membrane potential and induce subsequent changes in the channel conformation (Guy 19 
and Seetharamulu, 1986; Stuhmer et al., 1989). Especially the two small linkers 20 
between S1 – S2 and S3 – S4, but also residues in the transmembrane segments of the 21 
VSDs, present further extracellular binding sites for many gating modifier toxins like 22 
spider and scorpion toxins (de Lera Ruiz and Kraus, 2015; Murray et al., 2016). 23 
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 9 
Another important structural feature of the NaV channel α subunits is the third 1 
intracellular loop (L3) containing an IFM motif that connects S6 in DIII with S1 in 2 
DIV and is crucial for inactivation of the channel (Figure 1).  3 
While there is evidence for the importance of DIV for fast inactivation, the distinct 4 
functional roles of the three other domains is still uncertain (Ahern et al., 2016), partly 5 
due to a probable functional coupling between the different domains and a lack of 6 
more detailed structural information. 7 
 8 
Recent advances in single particle cryo-electron microscopy and membrane protein 9 
crystallography have improved our general structural understanding of voltage-gated 10 
ion channels, including the mammalian calcium and potassium channel (Hite et al., 11 
2015; Whicher and MacKinnon, 2016; Wu et al., 2015) and bacterial as well as 12 
eukaryotic NaV channels (Catterall, 2014; Shen et al., 2017). However, the exact 13 
three-dimensional structure of the pseudo-tetrameric human voltage-gated sodium 14 
channel α-subunits is still unknown due to difficulties with its crystallization. Several 15 
more or less accurate homology models exist, which are based on human NaV channel 16 
sequences and the X-ray crystal structures of homo-tetrameric prokaryotic NaV 17 
channels (NavAb, NavRh, and NavMs) (Catterall, 2014; McCusker et al., 2012; 18 
Payandeh et al., 2012; Payandeh et al., 2011; Zhang et al., 2012). One of the problems 19 
with these models is that the much simpler bacterial channels lack several important 20 
features of the eukaryotic version. Specifically, the four assembled identical subunits 21 
do not have the intracellular loops that connect the four corresponding human 22 
domains. Accordingly, the third loop (L3) with the conserved amino acid residues 23 
IFM between DIII and DIV, which is essential for fast inactivation of the open 24 
mammalian NaV channel (Stuhmer et al., 1989; Vassilev et al., 1989; West et al., 25 
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1992), is not conserved. Furthermore, a symmetrical bacterial channel cannot explain 1 
the distinct roles of the four individual domains, which each have different kinetics, 2 
functional properties and contributions to channel gating as well as unique binding 3 
sites for interacting compounds (Ahern et al., 2016). Another general problem of 4 
crystallography studies is the rigidity of the crystallized channels, which makes it 5 
difficult to analyse the in vivo flexible extracellular loops that determine the binding 6 
site of many channel modulators. Nevertheless, information on the general design of 7 
the NaV channels obtained from these studies is still helpful for a better understanding 8 
of these important proteins. With the continuing high interest in the field of NaV 9 
channels, it is likely that rapid advances in the field of high resolution single particle 10 
cryo-electron microscopy will lead to additional structural details on mammalian NaV 11 
channels in the near future (Sato et al., 2001; Slowik and Henderson, 2015). 12 
 13 
 14 
3.2.  Structure and function of β subunits 15 
When α subunits are heterologously expressed alone, they demonstrate full NaV 16 
channel function including sodium selectivity, rapid opening and fast inactivation 17 
(Goldin et al., 1986; Noda et al., 1986). However, in vivo they typically couple to one 18 
or two cell-type specific NaV channel β subunits, which do not contribute to the ion-19 
conducting pore but modulate channel function. This makes the coexpression of the 20 
appropriate β subunits in heterologous expression systems necessary to mimic the 21 
kinetic properties of native sodium channels. β subunits modify NaV channel gating 22 
properties including kinetics and voltage dependence as well as channel expression 23 
and trafficking (Catterall, 2000; Meadows and Isom, 2005; O'Malley and Isom, 2015). 24 
However, β subunits do not only modify sodium currents but have additional 25 
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functions as cell adhesion molecules, playing roles in cell adhesion, migration, 1 
invasion and neurite outgrowth (Brackenbury and Isom, 2011; Patino and Isom, 2 
2010). Furthermore, the β4 subunit has been found to function as an endogenous 3 
cytoplasmatic open channel blocker that directly competes with the fast inactivation 4 
gate and thus enabling resurgent currents, which render certain NaV channel isoforms 5 
capable of high-frequency firing in excitable tissues (Lewis and Raman, 2013). 6 
The identified genes SCN1B, SCN2B, SCN3B and SCN4B encode the four 7 
membrane bound β subunits β1 – β4 as well as a fifth soluble splice variant β1b. All 8 
are glycoproteins with a molecular weight of about 30 – 40 kDa, consisting of one 9 
single transmembrane domain (which is lacking in β1b) and an immunoglobulin-like 10 
extracellular domain. The subunits β1 and β3 interact non-covalently with α subunits, 11 
whereas β2 and β4 bind via disulfide bonds covalently to NaV channel α subunits.  12 
 13 
β Subunits are involved in several NaV channel-dependent pathologies, with changed 14 
expression levels in conditions like pain and nerve injury and genetic mutations in all 15 
four β subunit-encoding genes being linked to severe diseases (Eijkelkamp et al., 16 
2012).  17 
Interestingly, changing expression levels of β subunits in heterologous expression 18 
systems can significantly affect affinity and efficacy of activating and inhibitory 19 
toxins and thus alter NaV channel modulation (Gilchrist et al., 2013; Namadurai et al., 20 
2015). For instance, the presence of the β4 subunit dramatically reduces the inhibition 21 
of NaV1.2 by the spider toxin ProTx-II and decreases the maximal conductance of the 22 
same channel induced by the activating β-scorpion toxin TsVII, while not affecting its 23 
hyperpolarizing shift in voltage of activation. Co-expression of the NaV channel β2 24 
and β1 subunit significantly reduces the activation of NaV1.2 channels by the sea 25 
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anemone toxin ATX-II and the α-scorpion toxin LqqIV, respectively (Gilchrist et al., 1 
2013). β subunit co-expression can also alter the kinetics of NaV channel inhibition by 2 
pore blocking modulators of the conotoxin family. Binding on-rates (kon) of µ-3 
conotoxins at several NaV channel isoforms can be increased in the presence of β1 and 4 
β3 subunits, while they are decreased by β2 and β4 subunits (Zhang et al., 2013). In 5 
contrast, all four β subunits increase the kon of µO-conotoxin MrVIB at NaV1.8 6 
channels (Wilson et al., 2011). Furthermore, co-expression of β2 or β4 protects 7 
NaV1.1 -1.7 (excluding NaV1.5) channels against block by an analogue of the µO§-8 
conotoxin GVIIJ (Gajewiak et al., 2014). Thus, coexpression of β-subunits can 9 
strongly influence the affinity of conopeptides for NaV channels. 10 
 11 
Modification of toxin pharmacology by the presence of β subunits may thus explain 12 
some tissue-specific differences in pharmacological activity, as the expression levels 13 
of β subunits vary in different cell types (Gilchrist et al., 2013; Wilson et al., 2011). In 14 
addition, the expression of β subunits has implications for the use of NaV channel 15 
modulators in pathological conditions where β subunit expression is changed. 16 
 17 
3.3. Gating mechanisms of NaV channels: a toxin perspective 18 
NaV channels exist in at least three, and likely many more, distinct states: resting 19 
(closed), open, and inactivated (Figure 2). The process of channel gating refers to the 20 
movement of the voltage sensors in response to changes in charge distribution across 21 
the cellular membrane, resulting in structural re-arrangement of the channel. Toxins 22 
have been indispensable tools to understand the complex transitions between these 23 
states, and generally speaking interact with NaV channels either by physically 24 
occluding the pore, or by preventing movement of the voltage sensors either in the 25 
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outward or inward direction. Accordingly, to understand the pharmacological effects 1 
and mechanism of action of toxins, it is imperative to understand the gating 2 
mechanisms of NaV channels.  3 
 4 
In the resting or closed state of NaV channels, all four VSD are presumably in the 5 
“down” state as their positive gating charges on the S4 segments are forced toward the 6 
intracellular side of the cell membrane. This is due to the strong electrical potential 7 
generated by the negative resting membrane potential of unexcited neurons and 8 
myocytes. Membrane depolarization leads to activation and very quick opening of the 9 
channel as the more positive membrane potentials allow the S4 gating charges to 10 
move toward the extracellular surface into the “up” position. This likely involves a 11 
“helical screw” motion in which S4 helices slide and rotate around their axes, with the 12 
charged residues exchanging ion-pair partners until they are stabilised again by highly 13 
conserved negative charge clusters on the other segments (Chanda and Bezanilla, 14 
2002; Guy and Seetharamulu, 1986; Payandeh et al., 2011). The movement in VSDs 15 
is subsequently transferred to the PDs via the S4 - S5 linkers, changing channel 16 
conformation and allowing the pore to become permeable to sodium ions (Li et al., 17 
2014; Payandeh et al., 2011).  18 
Fast inactivation follows channel opening, resulting in a non-conducting inactivated 19 
channel state before finally recovering from inactivation and returning to a resting, 20 
closed state. Crucial for fast inactivation are the highly conserved residues IFM 21 
(isoleucine – phenylalanine - methionine) on the third intracellular loop between DIII 22 
and DIV (Vassilev et al., 1989; West et al., 1992), which bind to an unknown receptor 23 
site involving several residues of the S4 - S5 linker of DIV, close to the intracellular 24 
opening of the pore and thus closing it. The highly conserved DIV S4 - S5 linker is 25 
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made up of 15 amino acids of which 14 are identical in all nine human NaV channel 1 
isoforms. At least 7 of these residues have been found to be important for normal fast 2 
inactivation in various mutagenesis studies and have thus been proposed to be part of 3 
the putative receptor site of the docking region with the IFM motif (Filatov et al., 4 
1998; McPhee et al., 1998; Mitrovic et al., 1996; Tang et al., 1996). 5 
 6 
It is possible that there is functional coupling between the four VSDs that affects 7 
channel gating, but this is still unclear. Mutagenesis studies on S4 gating charges in 8 
the four VSDs hinted at a predominant role of DIV in fast inactivation (Kuhn and 9 
Greeff, 1999), while activation gating was affected by mutations of positive S4 10 
charges in all four voltage-sensing domains, but predominantly DI-DIII (Kontis et al., 11 
1997). Structure-function studies with toxins that bind to the DIV S3 - S4 linker of the 12 
VSD confirmed the role of DIV in fast inactivation (Benzinger et al., 1998; Rogers et 13 
al., 1996). The results suggest that fast inactivation can only occur after a 14 
conformational change in the VSD of domain IV makes it move toward the 15 
extracellular side of the cell membrane, while fast inactivation is independent from 16 
the movement of the VSDs of DI – DIII, which are likely to be mainly responsible for 17 
initial channel opening. Consistent with these findings is the observation that upon 18 
channel activation, the VSDs in DI - DIII move faster toward the extracellular surface 19 
with time-constants correlating to the fast channel opening, while the movement of 20 
the VSD in DIV is slower and correlates with the subsequent fast inactivation 21 
(Chanda and Bezanilla, 2002). Moreover, NaV channel modulating toxins that only 22 
bind to the DIV VSD usually have no effects on channel activation but inhibit or 23 
delay fast inactivation, resulting in slower decaying sodium currents. However, the 24 
separate functions of the kinetically different voltage sensors in DI - DIII still remain 25 
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to be defined. The DII and DIV VSDs are targeted by many natural modulators, but 1 
only very few toxins affect DI and DIII with binding sites rarely reported for these 2 
two domains (Bosmans et al., 2008). This suggests a predominant role of DII in NaV 3 
channel activation as it was probably evolutionarily the most successful to target. 4 
 5 
4. NaV activator pharmacology 6 
Due to its important role in action potential generation and propagation, many clinical 7 
drugs have been developed and numerous toxins from venomous animals or plants 8 
have evolved to target NaV channels, often as part of prey capture or defence 9 
strategies (Kaczorowski et al., 2008; Kalia et al., 2015). At least eight distinct binding 10 
sites on NaV channels (site 1-8) have been proposed, six of which are the receptor 11 
sites for various toxins (Catterall et al., 2005; de Lera Ruiz and Kraus, 2015). The 12 
definition of these binding sites is often complex as they include crucial amino acids 13 
on multiple domains and segments of the channel that significantly overlap with other 14 
binding sites. In a simplified model, binding sites can be differentiated structurally 15 
into the pore region and the voltage-sensing domains, with additional elaboration on 16 
functional effects distinguishing compounds that enhance or decrease channel 17 
activation, as well as those that enhance or decrease channel inactivation. According 18 
to the resultant effects on macroscopic NaV channel currents, these compounds can 19 
thus be classified as channel inhibitors or activators (Figure 3).  20 
Specifically, the pore region binding modulators can be functionally divided into pore 21 
occluding pore blocker (like tetrodotoxin and lidocaine) and compounds that facilitate 22 
or prolong channel activation by modifying gating after binding into the pore (e.g. 23 
veratridine). The VSD binding modulators can be broadly divided into another two 24 
groups. The first group – functional NaV channel activators – leads to an increase in 25 
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macroscopic Na+ current which can be induced by facilitating activation 1 
(hyperpolarizing shift in voltage of activation) and/or prolonging the open channel 2 
state (inhibition of inactivation). Examples of this group are discussed in more detail 3 
in the following sections. The second group – functional NaV channel inhibitors – 4 
leads to a decrease in Na+ current, induced by reduced activation (depolarizing shift in 5 
voltage of activation; e.g. ProTx-II) and/or shortened open channel states after 6 
binding to a VSD (e.g. Pn3a) (Deuis et al., 2017). 7 
 8 
NaV channel activators have provided crucial tool compounds to delineate the 9 
physiological and pathological roles of NaV channels, and may in future find 10 
applications as therapeutics for treatment of conditions such as epilepsy and cardiac 11 
arrhythmias. However, in contrast to NaV channel inhibitors, detailed pharmacological 12 
characterisation of NaV channel activators is relatively sparse, in part because more 13 
complex electrophysiological protocols may be required to determine effects on 14 
diverse gating parameters. Accordingly, it can be difficult to accurately define EC50 15 
values for NaV channel activators, which depend on distinct, and finite, effects on a 16 
single parameter.  17 
NaV channel activator toxins are typically gating modifiers toxins that bind either to 18 
the inside of the pore or to the extracellular parts of DII VSD and/or DIV VSD, 19 
sometimes involving extracellular pore domain residues in close proximity to the 20 
VSDs (Murray et al., 2016; Osteen et al., 2016). Gating modifiers modulate 21 
conformational changes of NaV channels and the coupling between the different 22 
channel states with varying effects on activating and inactivating gating properties. In 23 
general terms, activator toxins binding to DII VSD generally affect activation by 24 
shifting the voltage of activation to more hyperpolarized potentials, while activator 25 
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toxins that bind solely to the VSD of DIV generally affect inactivation by inhibiting 1 
normal movement of S4 and the subsequent inactivation of the channel (Xiao et al., 2 
2014). 3 
 4 
 5 
 6 
 7 
 8 
 9 
4.1. Classes of activators 10 
Due to their evolutionary success – based on the serious physiological effects caused 11 
by uncontrolled NaV channel activity – NaV channel activators are found in many 12 
different organisms, including plants, algae, frogs, cone snails, spiders, wasps, snakes, 13 
sea anemone and scorpions. In addition to alkaloid and polyether NaV channel 14 
activators, many of the venom-derived NaV channel activators are peptidic in nature, 15 
although the size, sequence and structure of these compounds is diverse. The NaV 16 
channel selectivity and toxin-channel interactions for each class of activators are 17 
discussed below, as well as being summarised in Table 1 and 2, respectively. It should 18 
be noted that potency might differ between human and rodent orthologs of NaV 19 
channels, however this is generally not assessed systematically. 20 
 21 
4.1.1. Alkaloid NaV channel activators 22 
Batrachotoxin, grayanotoxin, veratridine and aconitine are a chemically diverse group 23 
of NaV channel activators that share an overlapping binding site, designated as site 2 24 
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(Catterall, 1975). While often grouped together, these alkaloids have differential 1 
effects on the biophysical properties of NaV channels, all of which will be discussed 2 
individually below.  3 
Batrachotoxin, first isolated in 1965, is a lipophilic alkaloid secreted by the skin 4 
glands of poison dart frogs (Phyllobates spp.), used by native South Americans to 5 
poison the tips of blow-darts (Daly et al., 1965). Batrachotoxin is not produced by the 6 
frog itself, but is bioaccumulated through dietary consumption of alkaloids from 7 
insects, although the exact dietary source remains unknown (Daly et al., 1994). 8 
Accordingly, frogs raised in captivity do not secrete batrachotoxin, and due to 9 
difficulties in chemical synthesis, which were only recently overcome (Logan et al., 10 
2016), thousands of the now endangered Phyllobates poison dart frogs were captured 11 
and killed to isolate batrachotoxin (Daly et al., 1994). Symptoms of batrachotoxin 12 
intoxication include cardiac arrhythmias, motor impairment, respiratory depression 13 
and convulsions, which can lead to death (Albuquerque et al., 1971). 14 
Batrachotoxin preferentially binds to the open state of NaV channels, requiring 15 
repetitive depolarizing pulses (>1000) at a frequency of 1-2 Hz to observe a 16 
functional effect under voltage-clamp conditions (Wang and Wang, 1998). Once 17 
bound, batrachotoxin causes a hyperpolarizing shift in the voltage-dependence of 18 
activation, inhibits fast and slow inactivation, and causes a change in ion selectivity 19 
(Bosmans et al., 2004; Li et al., 2002; Wang and Wang, 1996; Wang and Wang, 20 
1998). Batrachotoxin has an EC50 of 1 µM, and displays little NaV channel selectivity, 21 
inhibiting fast inactivation of NaV1.2, NaV1.3, NaV1.4, NaV1.5, NaV1.7 and NaV1.8 22 
with a similar effect at a concentration of 10 µM (Bosmans et al., 2004; Li et al., 23 
2002; Logan et al., 2016).  24 
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The binding site of batrachotoxin is located within the inner pore region, with single 1 
point mutations of amino acids located on S6 in DI (I433, N434, L437), DII (N784, 2 
L788), DIII (F1236, S1276, L1280) and DIV (F1579, N1584) causing rNaV1.4 to 3 
become insensitive to the effects of batrachotoxin (Figure 4-8) (Toma et al., 2016; 4 
Wang et al., 2001; Wang et al., 2000b; Wang and Wang, 1998, 1999). These amino 5 
acids are conserved on hNaV1.1-1.8, accounting for the limited selectivity of 6 
batrachotoxin for NaV channels. Interestingly, sequence alignment of frog NaV1.4 has 7 
identified similar single point mutations in Phyllobates poison dart frogs on S6 DI 8 
(S429A, I433V, A446D) and S6 DIV (V1583I, N1584T), conferring resistance to 9 
protect against self-intoxication (Tarvin et al., 2016).   10 
 11 
Grayanotoxin is present in the leaves, twigs and flowers of Rhododendron plants. In 12 
humans, intoxication can occur by consumption of honey (known as “mad honey”) 13 
produced by bees from the nectar of Rhododendron plants, with most reported cases 14 
occurring from honey originating from Turkey (Gunduz et al., 2006). Mad honey 15 
poisoning causes nausea, vomiting, dizziness, hypotension, bradycardia and other 16 
cardiac disturbances, which can be fatal if left untreated.   17 
Like batrachotoxin, grayanotoxin binds to the open state of NaV channels and requires 18 
repetitive depolarising pulses to see a functional effect under voltage-clamp 19 
conditions (Yakehiro et al., 2000).  Once bound, grayanotoxin causes a 20 
hyperpolarizing shift in the voltage-dependence of activation, but unlike 21 
batrachotoxin, causes a reduction in peak current (Kimura et al., 2001). Grayanotoxin 22 
also inhibits fast inactivation and causes a reduction in ion selectivity, similar to 23 
batrachotoxin (Yuki et al., 2001). Compared with batrachotoxin, grayanotoxin is less 24 
potent, with an EC50 of 31 µM, and has a greater effect on fast inactivation at NaV1.4 25 
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compared to NaV1.5, although activity at other NaV channel subtypes in heterologous 1 
expression systems remains to be determined (Kimura et al., 2001; Yakehiro et al., 2 
2000).  3 
The binding site of grayanotoxin is less well defined, with studies focused on 4 
assessing the activity of grayanotoxin on rNaV1.4 channels with single point 5 
mutations known to cause batrachotoxin insensitivity. While single point mutations of 6 
amino acids located on S6 in DI (I433, N434, L437) cause grayanotoxin insensitivity, 7 
activity is maintained with the single point mutation F1579A on S6 in DIV, indicating 8 
that grayanotoxin and batrachotoxin share an overlapping but non-identical binding 9 
site (Figure 4) (Ishii et al., 1999; Kimura et al., 2000). In addition, the poison dart 10 
species Phyllobates terribilis is insensitive to batrachotoxin, but not to grayanotoxin, 11 
confirming a non-identical binding site (Daly et al., 1980).  12 
 13 
Veratridine is a steroid-derived alkaloid found in the roots of Veratrum plants from 14 
the Liliaceae family. Unlike batrachotoxin and grayanotoxin, veratridine does not 15 
require repetitive depolarising pulses to exert a functional effect on NaV channels 16 
under voltage-clamp conditions (Farrag et al., 2008; Ghatpande and Sikdar, 1999). 17 
Veratridine causes a hyperpolarising shift in the voltage-dependence of activation and 18 
decreases peak current, however compared to batrachotoxin and grayanotoxin, only 19 
delays rather than inhibits fast inactivation, resulting in a comparatively small 20 
persistent current (Ghatpande and Sikdar, 1999). Veratridine has an EC50 of 29 µM at 21 
NaV1.7, and appears to have minimal selectivity at NaV1.1-1.7, based on its use as a 22 
NaV channel activator in fluorescence based assays (Deuis et al., 2015; Vetter et al., 23 
2012a; Vickery et al., 2004). In rodent dorsal root ganglion neurons, veratridine 24 
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causes persistent current in TTXs channels but not in TTXr channels, suggesting 1 
differential effects on NaV1.8 and NaV1.9 (Farrag et al., 2008). 2 
Veratridine shares an overlapping but non-identical binding site with batrachotoxin, 3 
as the poison dart species Phyllobates terribilis is sensitive to veratridine, but not 4 
batrachotoxin (Daly et al., 1980). In addition, single point mutations of amino acids 5 
located on S6 in DI (I433, N434, L437) and S6 in DIV (F1579, N1584) cause rNaV1.4 6 
to become insensitive to the inactivation-modulating effects of veratridine (Figure 4 7 
and 8), although all of the mutants remained sensitive to the inhibitory effects of 8 
veratridine on peak current (Wang et al., 2000a). The reason for this disparity remains 9 
unclear, but suggests that the persistent current and reduction in peak current are 10 
caused by two distinct channel interactions.  The most likely explanation is that peak 11 
current is reduced after binding of veratridine due to partial occlusion of the ion 12 
permeation pathway, while gating/inactivation cannot be modulated anymore in these 13 
mutants due to removal of the essential gating-modifying interactions.  14 
 15 
Aconitine is a steroid-derived alkaloid found in the Aconitum napellus (monkshood) 16 
plant. Like batrachotoxin and grayanotoxin, aconitine preferentially binds to the open 17 
channel state, requiring repetitive depolarising pulses to see a functional effect under 18 
voltage-clamp conditions (Rao and Sikdar, 2000). Aconitine causes a hyperpolarising 19 
shift in the voltage-dependence of activation, inhibits peak current, slows the rate of 20 
fast inactivation (although aconitine-modified channels can inactivate completely), 21 
and causes a reduction in ion selectivity (Rao and Sikdar, 2000; Wright, 2002). 22 
Aconitine has similar pharmacological effects at NaV1.2, NaV1.4 and NaV1.5, 23 
although a small persistent current is seen at NaV1.5 only (Rao and Sikdar, 2000; 24 
Wright, 2002). Activity at other NaV channel subtypes in heterologous expression 25 
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systems remains to be determined. The binding site is assumed to overlap with other 1 
site 2 toxins, based on similar chemical structures and mechanism of action, although 2 
this remains to be experimentally confirmed. 3 
 4 
4.1.2. Spider-venom derived NaV channel activators 5 
Spider venom-derived peptides have diverse pharmacological effects at NaV channels 6 
as they can interact with different voltage sensor(s). The resultant effects including 7 
inhibition of channel opening, a shift the voltage-dependence of activation, and/or a 8 
delay in fast inactivation.  In general, spider venom-derived peptides that interact 9 
exclusively with DIV delay fast inactivation, while peptides that interact with DI-III 10 
result in inhibition of channel opening and/or shifts in the voltage-dependence of 11 
activation (Bosmans et al., 2008). Accordingly, spider venom-derived peptides are 12 
named using Greek symbols that denote their pharmacological activity, with the 13 
prefix µ-, β-, or δ- used to described toxins that inhibit NaV channels, toxins that shift 14 
the voltage dependence of activation or toxins that delay fast inactivation, 15 
respectively, followed by taxonomic family, then a genus/species and numerical 16 
descriptor (King et al., 2008). For consistency, the nomenclature utilised in 17 
ArachnoServer will be used to identify spider venom-derived peptides in this review 18 
and peptides will be grouped into Family’s 1-12 based on sequence homology as 19 
proposed by Klint et al. (Herzig et al., 2011; Klint et al., 2012).  20 
Venom from two Australian funnel-web spider species, Atrax robustus and 21 
Hadronyche versuta, and the Australian eastern mouse spider Missulena bradleyi are 22 
the source of four homologous NaV channel activator toxins consisting of 42 amino 23 
acid residues belonging to Family 4, named δ-hexatoxin-Ar1a (formally robustoxin), 24 
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δ-hexatoxin-Hv1a (formally versutoxin), δ-hexatoxin-Hv1b and δ-actinopoditoxin-1 
Mb1a. In dissociated rat DRG neurons, these toxins potently inhibit fast inactivation 2 
of TTX-sensitive channels, with no effect on TTX-resistant channels (Alewood et al., 3 
2003; Gunning et al., 2003; Nicholson et al., 1996; Nicholson et al., 1998; Szeto et al., 4 
2000). Consistent with this activity, δ-hexatoxin-Ar1a and δ-hexatoxin-Hv1a 5 
competitively inhibit binding of the α-scorpion toxin Lqh II in rat brain synaptosomes, 6 
indicating they interact with DIV (Little et al., 1998). In addition, these toxins also 7 
cause a hyperpolarizing shift in the voltage-dependence of activation and voltage-8 
dependence of steady-state inactivation (Alewood et al., 2003; Gunning et al., 2003; 9 
Nicholson et al., 1996; Nicholson et al., 1998; Szeto et al., 2000), suggesting 10 
additional interactions with DII, although the exact binding site(s) of this family 11 
remains to be elucidated. The only member of Family 4 to be characterised at NaV1.1-12 
1.8 is δ-hexatoxin-Mg1a (formally Magi 4) from the Japanese funnel-web spider 13 
Macrothele gigas. At a concentration of 5 µM, δ-hexatoxin-Mg1a delays fast 14 
inactivation, with a large effect at NaV1.1 and NaV1.6, a comparatively smaller effect 15 
at NaV1.2, NaV1.3 and NaV1.7, and no effect at NaV1.4, NaV1.5 and NaV1.8 (Yamaji 16 
et al., 2009). Like members of the Family 4 isolated from Australian spiders, δ-17 
hexatoxin-Mg1a also shifts the voltage-dependence of activation to more 18 
hyperpolarized potentials. 19 
Another NaV channel activator isolated from the Japanese funnel-web spider 20 
Macrothele gigas is β-hexatoxin-Mg1a (formally Magi 5; also identical primary 21 
sequence to β-hexatoxin-Mr1a from Macrothele raveni), a 29-residue peptide that has 22 
little sequence homology to δ-hexatoxin-Mg1a and belongs to Family 5 (Corzo et al., 23 
2007; Zeng et al., 2003). β-hexatoxin-Mg1a has only been characterised at NaV1.2, 24 
where it shifts the voltage-dependence of activation to more hyperpolarized 25 
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potentials, with no effect on the rate of fast inactivation (Corzo et al., 2007). 1 
Consistent with this activity, in rat brain synaptosomes β-hexatoxin-Mg1a 2 
competitively inhibits binding of the β-scorpion CssIV, but not the α-scorpion toxin 3 
Lqh II, indicating it interacts with the DII voltage sensing domain (Corzo et al., 2003). 4 
Over 90 peptides have been sequenced from the venom of the Chinese tarantula 5 
species Chilobrachys guangxiensis (also known as Chilobrachys jingzhao). While the 6 
pharmacological activity of most of these peptides remains to be confirmed, several 7 
have been identified NaV channel activators (Chen et al., 2008). δ-theraphotoxin-Cg1a 8 
(formally Jingzhaotoxin-I) and δ-theraphotoxin-Cg3a (formally Jingzhaotoxin-II) 9 
consist of 33 and 32 amino acid residues, respectively, with ~ 50% sequence 10 
homology and belong to Family 7 (Wang et al., 2008b; Xiao et al., 2005). Both δ-11 
theraphotoxin-Cg1a and δ-theraphotoxin-Cg3a have similar pharmacological activity 12 
and delay inactivation of NaV channels, with little to no effect on the voltage-13 
dependence of activation or steady state inactivation (Huang et al., 2015; Tao et al., 14 
2016; Wang et al., 2008b; Xiao et al., 2005). Consistent with effects on inactivation, 15 
site directed mutagenesis of D1609A on hNaV1.5, which is located on the DIVS3-S4 16 
linker (Figure 9), causes both δ-theraphotoxin-Cg1a and δ-theraphotoxin-Cg3a to 17 
lose activity, confirming that these peptides interact with the voltage-sensing domain 18 
of DIV (Huang et al., 2015; Tao et al., 2016). Interestingly, the selectivity profiles of 19 
these peptides differs from each other, with δ-theraphotoxin-Cg3a most potently 20 
delaying inactivation at NaV1.5 (EC50 125 nM), with minor effects on NaV1.3, NaV1.4 21 
and NaV1.7 at 5 µM, whilst δ-theraphotoxin-Cg1a is comparatively non-selective, 22 
delaying inactivation at NaV1.2, NaV1.3, NaV1.4, NaV1.5 and NaV1.7 with similar 23 
potency (EC50 335-870 nM) (Huang et al., 2015; Tao et al., 2016). At higher 24 
concentrations, δ-theraphotoxin-Cg1a also inhibits KV2.1 (Tao et al., 2013). 25 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 25
δ-theraphotoxin-Cg2a (formally Jingzhaotoxin-IV) is a 34-residue peptide also from 1 
the venom of Chilobrachys guangxiensis, but that shares sequence homology to 2 
Family 2. It delays inactivation of TTX-sensitive channels in rat DRG neurons, but 3 
unlike the other spider-venom derived NaV channel activators described so far, causes 4 
a depolarising shift in the voltage-dependence of activation, as well as a 5 
hyperpolarising shift in the voltage-dependence of inactivation (Wang et al., 2008a). 6 
The binding site of δ-theraphotoxin-Cg2a remains to be elucidated but based on its 7 
pharmacological activity, is likely to involve interactions with DII and DIV. While 8 
interactions with other domains cannot be ruled out, DIII interactions are yet to be 9 
described for spider toxins. Full NaV channel selectivity is not available for δ-10 
theraphotoxin-Cg2a. 11 
Many members of Family 2 inhibit KV channels (denoted by the prefix κ). Despite 12 
being originally identified as KV inhibitors, an increasing number of peptides from 13 
Family 2 are being found to act on NaV channels. One notable example is δ-14 
theraphotoxin-Hm1a, which was originally described as a KV2 and KV4 inhibitor.  15 
Interestingly, Hm1a selectively delays inactivation of NaV1.1 (EC50 38 nM), with no 16 
effect on NaV1.2-1.8 at a concentration of 100 nM (Osteen et al., 2016). Construction 17 
of KV2.1/hNaV1.1 chimeric channels, where the S3-S4 linker from each domain of 18 
hNaV1.1 is inserted into the homotetrameric KV2.1 channel, has identified that δ-19 
theraphotoxin-Hm1a binds exclusively to DIV, consistent with its pharmacological 20 
activity (Figure 9 and 10) (Osteen et al., 2016).  21 
 22 
4.1.3. Wasp venom-derived NaV channel activators 23 
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Two 13 amino acid residue peptides, named α-pompilidotoxin and β-pompilidotoxin, 1 
isolated from the venom of the solitary wasps Anoplius samariensis and Batozonellus 2 
maculifrons, respectively, are known to activate NaV channels (Konno et al., 1998). 3 
They are highly homologous, differing by only one amino acid, with most work 4 
carried out using β-pompilidotoxin, as it is 5 times more potent than α-pompilidotoxin 5 
(Konno et al., 2000).  6 
β-pompilidotoxin has some selectivity between NaV channels subtypes: it delays fast 7 
inactivation at NaV1.1, NaV1.2 (EC50 21 µM), NaV1.3 (EC50 99 µM), and NaV1.7, 8 
inhibits fast inactivation at NaV1.6 (EC50 30 µM), and has no effect on the fast 9 
inactivation kinetics of NaV1.4 and NaV1.5 (up to 140 µM) (Schiavon et al., 2010). 10 
Using a range of rNaV1.2/rNaV1.5 channel chimeras, the binding site of β-11 
pompilidotoxin was identified as the S3-S4 linker of DIV, consistent with its 12 
pharmacological effects on delaying fast inactivation (Kinoshita et al., 2001). The 13 
amino acid E1616 in the S3-S4 linker of DIV rNaV1.2, which is conserved in NaV1.1, 14 
NaV1.2, NaV1.3, NaV1.6, NaV1.7 but not in NaV1.4 or NaV1.5, is essential for β-15 
pompilidotoxin binding, and accounts for this NaV channel selectivity profile (Figure 16 
9) (Kinoshita et al., 2001).  17 
 18 
4.1.4. Snake venom-derived NaV channel activators 19 
Three-finger toxins (3FTxs) are a large family of snake venom-derived toxins with a 20 
conserved structural fold but diverse pharmacology, which includes activity at 21 
nicotinic and muscarinic acetylcholine receptors, acetylcholinesterase and L-type 22 
voltage-gated calcium channels (Kini and Doley, 2010). δ-calliotoxin, a 57-amino 23 
acid residue peptide isolated from the long-glanded blue coral snake (Calliophis 24 
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bivirgatus), is the first 3FTx to be identified as a NaV channel activator (Yang et al., 1 
2016). At NaV1.4, δ-calliotoxin (200 nM) causes a small hyperpolarising shift in the 2 
voltage-dependence of activation and delays fast inactivation, as well as causing a 3 
persistent current (Yang et al., 2016). Activity and selectivity at other NaV channel 4 
subtypes remains to be determined. Although the binding site of δ-calliotoxin has not 5 
yet been defined, based on its pharmacological activity, it likely involves interactions 6 
with residues of DIV. 7 
 8 
 9 
4.1.5. Scorpion venom NaV channel activators 10 
Scorpion neurotoxins that act on NaV channels are broadly categorised as α or β toxins 11 
– both of which contain 60-80 amino acids linked by four disulphide bridges – based 12 
on their effects on the electrophysiological properties of NaV channels. This 13 
functional distinction is a reflection of distinct binding sites on NaV channels 14 
(Bosmans and Tytgat, 2007; Pedraza Escalona and Possani, 2013), with α toxins 15 
binding to site 3 to cause a delay in fast inactivation (Gordon et al., 1996). In contrast, 16 
β-scorpion toxins bind to site 4 and alter the threshold for activation, allowing channel 17 
opening at hyperpolarized potentials whilst also reducing peak current (Couraud et al., 18 
1982). Thus, both α- and β-scorpion toxins are appropriately described as NaV 19 
channels activators albeit with a distinct mechanism of action. Scorpion neurotoxins 20 
have proved useful in characterising NaV channel binding sites and function, although 21 
it is important to note that with increased understanding of NaV channel structure, a 22 
more complex picture of toxin binding has emerged. For brevity, here we discuss only 23 
those toxins that are only active at mammalian NaV channels and also display some 24 
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selectivity across the isoforms (for comprehensive review of scorpion toxins see 1 
(Housley et al., 2016)).   2 
 3 
Structural and functional assessment of α-scorpion toxins has led to a model of toxin 4 
binding that impairs the movement of the VSD of domain IV (Cestele and Catterall, 5 
2000), which as detailed above, is critical for inactivation but not activation gating. 6 
Experimentally, classical α scorpion binding to site 3 manifests as a delay in 7 
inactivation without major changes in channel activation (Bosmans and Tytgat, 2007). 8 
Furthermore, α-scorpion toxins, which can in addition be classified into α or α-like 9 
based on functional effects and target species, may be “pulsed off” with strong 10 
depolarizations (Bosmans and Tytgat, 2007; Campos et al., 2004; Catterall, 1977). 11 
The classical old world toxin, AaHII, isolated from Androctonus australis, is a 12 
prototypical α-scorpion toxin. The selectivity of AaHII has not been reported, 13 
however it readily binds to rat brain synaptosomes presumably expressing NaV1.2 14 
(Legros et al., 2005). 15 
 16 
Venom from Leiurus quinquestriatus hebraeus contains α-toxins LqhII and LqhIII 17 
that are highly toxic to mammals (Sautiere et al., 1998). LqhII and LqhIII modulate 18 
NaV1.4 and NaV1.5 by removing fast inactivation as described above (Chen et al., 19 
2000; Chen and Heinemann, 2001). Additionally, LqhII and III enhance slow 20 
inactivation of NaV1.5 as some of the first α-scorpion toxins to cause this 21 
phenomenon (Chen and Heinemann, 2001). LqhIII also alters the kinetics of hNaV1.2 22 
and hNaV1.7 and is known as an α-like toxin, binding to both mammalian and insect 23 
NaV channels, but not rat synaptosomes (Chen et al., 2002; Gilles et al., 2000). LqTx 24 
(Leiurus quinquestriatus quinquestriatus) highlighted the crucial role for E1613 25 
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(rNaV1.2) in site 3 toxin binding (Rogers et al., 1996), which was further investigated 1 
with LqhII and LqhIII. Interestingly, D1428 of rNaV1.4 (analogous to E1613 rNaV1.2) 2 
is critical to LqhIII but not LqhII binding (Leipold et al., 2004). LqhII relies on 3 
residues Y1433, F1434 and V1435 of DIV S3-S4 linker (rNaV1.4) as site directed 4 
mutagenesis causes loss of activity (Figure 9) (Leipold et al., 2005). Furthermore, a 5 
secondary interaction site for LqhII is present in the DI S5-S6 linker (Wang et al., 6 
2011). In particular, an alanine scan of DI highlighted T393 (rNaV 1.2) as a crucial 7 
binding partner of LqhII (Figure 11).  8 
 9 
The α-scorpion toxin OD1, isolated from the Iranian scorpion Odonthobuthus doriae 10 
was initially described to interact with the insect NaV channel isoform para/tipE. 11 
However, OD1 is also an activator of hNaV1.7, hNaV1.4 and hNaV1.6 as measured by 12 
fluorescence based assays and electrophysiology (Durek et al., 2013a). At low 13 
nanomolar concentrations, OD1 significantly impairs inactivation of NaV1.7 14 
(Maertens et al., 2006b; Motin et al., 2016), while at higher concentrations (300 nM), 15 
OD1 also causes a hyperpolarising shift in the voltage dependence of activation, 16 
considerably increases peak current values and induces a large persistent current 17 
(Deuis et al., 2016b).  18 
Ts2, from T. serrulatus, prevents inactivation of rat NaV1.2, NaV1.3, NaV1.5, NaV1.6 19 
and NaV1.7 (Cologna et al., 2012). However, Ts2 also selectively shifts the voltage 20 
dependence of activation of rNaV1.3 (Cologna et al., 2012). Accordingly, although 21 
Ts2 is currently classified as an α scorpion toxin, this specific activation of rNaV1.3 is 22 
similar to β-scorpion Tf2 discussed below. Thus, the mixed pharmacological effects 23 
of both OD1 and Ts2 blur the line between α- and β- scorpion toxins, inviting a 24 
revision of the classification these NaV channel activators. 25 
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 1 
MeuNaTxαs are a large family of thirteen α-scorpion toxins isolated from the 2 
scorpion Mesobuthus eupeus. Of these, the pharmacological activity of MeuNaTxα-1, 3 
2 and 5 has been comprehensibly characterized. MeuNaTxα-1 modulates NaV1.2, 4 
NaV1.3, NaV1.6 and NaV1.7, MeuNaTxα-2 affects NaV1.4 only, whereas MeuNaTxα-5 
5 is the least selective modulating NaV1.3-1.7 (Zhu et al., 2012). These peptides also 6 
potently slow inactivation in the insect channel counterpart DmNaV1. MeuNaTxα-12 7 
and MeuNaTxα-13 also preferentially affect NaV1.1 (Zhu et al., 2013).  8 
Bot IX, from Buthus occitanus tunetanus is a recently reported α-like toxin, inhibiting 9 
fast inactivation at both insect NaV and rNaV1.2 (Martin-Eauclaire et al., 2016). 10 
However, Bot IX also competed with AaHII binding, the first α-like toxin described 11 
to do so (Martin-Eauclaire et al., 2016). Full selectivity of Bot IX at mammalian NaV 12 
channel isoforms is unknown.  13 
 14 
Scorpions of the genus Centruroides produce several peptides that were critical for 15 
early understanding of the mechanics of the VSD in NaV channels (Cestele et al., 16 
1998). Specifically, the class of β-scorpion toxins was based on characterisation of 17 
CssIV, from C. suffusus suffusus, which shifts the voltage dependence of activation of 18 
NaV1.1, 1.2 and 1.6 (Jover, 1980; Jover et al., 1980; Karbat et al., 2010; Schiavon et 19 
al., 2006). This activity is explained through a voltage sensor trapping mechanism 20 
whereby the peptide binds to the activated position of the DII VSD (both S1-S2 and 21 
S3-S4 extracellular loops), locking it in an activated position (Cestele et al., 1998; 22 
Pedraza Escalona and Possani, 2013; Zhang et al., 2011). Regions crucial for CssIV 23 
binding are found in DI S5-S6, DII S1-S2 and S3-S4 linkers and various residues 24 
located in the DIII S5-S6 linker (Cestele et al., 1998). This includes P782 (DII S1-S2) 25 
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and G845 (DII S3-S4) in rNaV1.2, which when substituted for asparagine result in 1 
reduced CssIV binding and in the case of G845, a loss of activity. Within the DIII S5-2 
S6 linker, mutations of N1436, E1438, L1439 and D1445 (rNaV1.2) cause changes in 3 
CssIV binding and voltage-sensor trapping activity (Figure 6 and 11 - 13) (Zhang et 4 
al., 2011).   5 
Similarly, the β scorpion toxin Cn2, originally purified as fraction II-10 from the 6 
crude venom of Centruroides noxius Hoffmann, is particularly notable for its high 7 
selectivity for hNaV1.6 (Schiavon et al., 2006). Cn2 causes a robust hyperpolarising 8 
shift in activation permitting NaV1.6 opening at usually prohibitive membrane 9 
potentials, albeit this effect is only observed during protocols that includes a prepulse 10 
to allow toxin binding (Cestele et al., 1998; Schiavon et al., 2006).   11 
Intriguingly, Cn2 also enhances resurgent currents in Purkinje neurons (Schiavon et 12 
al., 2006), where non-conducting (inactivated) Nav channels are seen to reopen 13 
(resurge) in response to mild repolarization steps from positive potentials (Raman and 14 
Bean, 1997). This resurgent current is reduced by 90% in NaV1.6 KO mice leading to 15 
the identification of NaV1.6 as the primary channel responsible for carrying his 16 
current (Raman et al., 1997). Resurgent currents are thought to allow high frequency 17 
firing in neurons and may be involved in clinical disease states such as paroxysmal 18 
extreme pain disorder and chemotherapy induced cold allodynia (Jarecki et al., 2010; 19 
Sittl et al., 2012) Interestingly, although CssIV has 83% sequence homology with Cn2 20 
and is capable of binding NaV1.6, it does not produce a resurgent current (Schiavon et 21 
al., 2006). Thus, Cn2 may find future application as a probe to understand the 22 
intricacies of resurgent current in vitro and in vivo.  23 
The genus of Tityus scorpions, whose habitat ranges from Central to South America, 24 
has provided several β-scorpion toxins with interesting pharmacological properties. 25 
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For example, Ts1 from T. serrulatus shifts the voltage dependence of activation of 1 
NaV1.2, 1.4 and NaV1.6 and also decreases peak current of NaV1.6, and to a lesser 2 
extent NaV1.4 (Peigneur et al., 2015a). Interestingly, this toxin also exerts a full block 3 
of NaV1.5 without changes in activation or inactivation (Peigneur et al., 2015a). In 4 
contrast, Tz1 from T. zulianus also modulates the activity of NaV1.4 > NaV1.6 > 5 
NaV1.2 but not NaV1.5 and NaV1.7 (Leipold et al., 2006). NaV channel residues 6 
involved in Tz1 activity are shown in Figure 6 and 13. Highlighting the 7 
pharmacological diversity of scorpion toxins, Tf2 from T. fasciolatus selectively 8 
causes the opening hNaV1.3 at hyperpolarized membrane potentials (Camargos et al., 9 
2015) with no effect (activation or inactivation) on other NaV channel isoforms. This 10 
highly specific activation of a singular NaV channel isoform may be useful as a tool to 11 
delineate the physiological and pathological role of NaV1.3 (Hains et al., 2003; Hains 12 
et al., 2005; He et al., 2010).  13 
 14 
4.1.6. Cone snail venom derived NaV channel activators 15 
Marine snails of the genus Conus have evolved a complex cocktail of venom peptides 16 
(conotoxins) for both predatory and defensive behaviour (Dutertre et al., 2013; Lewis 17 
et al., 2012). These small peptides are universally cysteine-rich and folded with 18 
multiple disulfide bridges (Han et al., 2008; Lewis et al., 2012; Vetter and Lewis, 19 
2012). Conotoxins of the µ-, µΟ-, δ- and ι families target NaV channels via a variety 20 
of mechanisms (Ekberg et al., 2008; Green and Olivera, 2016). However, as µ- and 21 
µΟ-conotoxins are NaV channel inhibitors this review will focus on δ- and ι-22 
conotoxins.  23 
 24 
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δ-Conotoxins inhibit fast inactivation and modulate the voltage-dependence of 1 
activation of NaV channels (Ekberg et al., 2008; Stevens et al., 2011). The result of 2 
this hyperpolarizing shift is prolonged channel opening and thus, persistent firing of 3 
excitable cells (Ekberg et al., 2008). In-depth information regarding structure-function 4 
relationship between δ-conotoxins and their NaV channel targets is sparse owing in 5 
part to challenges in chemical synthesis and the extreme hydrophobicity of these 6 
peptides. Thus, the exact binding site of the δ-conotoxins remains a point of 7 
contention. As their pharmacological effects are similar to those of the α-scorpion 8 
toxins, site 3 was proposed as a binding site; however, δ-conotoxins do not fully 9 
compete with site 3 toxins (Fainzilber et al., 1994; Leipold et al., 2005). Furthermore, 10 
site-directed mutagenesis of this region failed to alter all biophysical properties 11 
associated with δ-conotoxin binding (Leipold et al., 2005). SVIE (Conus striatus) 12 
interacts with a hydrophobic triad of the DIV S3-S4 linker, Y1433–F1434–V1435 13 
(rNaV1.4) (Figure 9) (Leipold et al., 2005). Thus, a new binding site (site 6) was 14 
suggested, although it remains poorly defined.  15 
 16 
While δ-conotoxins are commonly found in vermivorous or piscivorous Conidae and 17 
activity at NaV channel homologues of worms and fish might contribute to the use of 18 
these peptides in prey capture, they also affect mammalian NaV channels. For 19 
example, δ-EVIA, isolated from C. ermineus, inhibits fast inactivation of rNaV1.2, 20 
rNaV1.3 and rNaV1.6 without altering rNaV1.4 and hNaV1.5 (Barbier et al., 2004; 21 
Volpon et al., 2004). In addition, δ-Am2766 from C. amadis inhibits inactivation of 22 
rNaV1.2, albeit activity at other subtypes is unknown (Sarma et al., 2005). 23 
Interestingly, δ-SuVIA, isolated from the vermivorous C. suturatus, is active at low 24 
nanomolar concentrations at hNaV1.3, hNaV1.4, hNaV1.6 and hNaV1.7 (Jin et al., 25 
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2015). This defensive conotoxin causes a hyperpolarizing shift in activation potential 1 
at hNaV1.7 but fails to measurably modify inactivation kinetics (Jin et al., 2015). This 2 
is at clear odds with other δ-conotoxins studied from fish-hunting Conus and may 3 
suggest a different class of conotoxin altogether. 4 
The superfamily of I1 conotoxins was initially identified in the venom of C. radiatus 5 
(Jimenez et al., 2003). These peptides contain a unique cysteine backbone structure 6 
with four disulfide bonds (Buczek et al., 2007). ι-conotoxin RXIA shifts the voltage-7 
dependence of activation, without altering inactivation, most potently at rNaV1.6 8 
(EC50 2 µM) followed by rNaV1.2 and rNaV1.7 (Fiedler et al., 2008). As ι-RXIA had 9 
no effect on other subtypes tested, the ι-conotoxins may provide an additional source 10 
of selective agonist peptides.  11 
Additionally, tetrodotoxin-sensitive current in DRGs were enhanced by M-12 
superfamily toxin, LtIIIA isolated from C. litteratus (Wang et al., 2009). Given that 13 
DRGs express a range of NaV channel isoforms, the selectivity of this peptide is 14 
unknown.  15 
4.1.7. Sea anemone derived NaV channel activators 16 
Sea anemone toxins that associate with NaV channels are categorised into three 17 
groups: Type I, II and III (Frazao et al., 2012; Moran et al., 2009; Norton, 1991). 18 
However, in recent years questions about the validity of these broad classifications 19 
have arisen as additional peptides are discovered and characterised that diverge from 20 
the stringent structural and functional properties proposed originally (Ishida et al., 21 
1997; Moran et al., 2009). Sea anemone toxins bind to site 3 and produce a delay in 22 
inactivation at low concentrations as well as a large persistent current at high 23 
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concentrations (Catterall and Beress, 1978; Moran et al., 2007; Smith and 1 
Blumenthal, 2007). ATX-II binds the DIV S3-S4 linker, in particular E1613 2 
(rNaV1.2) where charge inversion at this point results in no binding (Rogers et al., 3 
1996). This is direct evidence for the overlap between ATX-II and other site 3 toxins 4 
including LqTx described above. Furthermore E1616, V1620 and L1624 alanine 5 
substitutions resulted in lower binding affinity of ATX-II but not LqTx (Figure 9). 6 
Altering the corresponding amino acid of rNaV1.5, D1612, decreased binding affinity 7 
for ApB (Anthopleura xanthogrammica) (Benzinger et al., 1998). Taken together, this 8 
region of the DIV S3-S4 loop is indeed central to sea anemone toxin binding. The 9 
NaV channel subtype selectivity for mammalian isoforms has been systematically 10 
assessed for a limited number of peptides, including ATX-II, AFT-II and Bc-III 11 
isolated from Anemonia sulcata, Anthopleura fuscoviridi and Bunodosoma 12 
granulifera, respectively (Bosmans et al., 2002; Oliveira et al., 2004).  Although these 13 
toxins display differential effects at NaV1.1-1.6, none are truly selective activators 14 
(Table 1) (Oliveira et al., 2004).  15 
 16 
Other NaV channel activators present in sea anemone venom include CGTX-II and δ-17 
AITX-Bcg1a, from Bunodosoma cangicum. CGTX-II interacts with hNaV1.5 over 18 
NaV1.6 with minor affects at NaV1.1, 1.2, 1.3, 1.4 and 1.7 (Zaharenko et al., 2012). 19 
Interestingly, CGTX-II causes a depolarizing shift in the inactivation curve of only 20 
hNaV1.5, whereas the effect on hNaV1.6 includes a large non-inactivating window 21 
current (Zaharenko et al., 2012).  While the molecular basis of these differential 22 
effects remains unclear to date, these pharmacological effects may provide additional 23 
insight into NaV channel gating mechanisms and structural motifs contributing to 24 
effects on channel activation and inactivation. 25 
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 1 
4.1.8. Dinoflagellate and bacterial NaV channel activators  2 
NaV channel activators of marine dinoflagellate origins are the cause of several 3 
seafood related food poisoning diseases including ciguatera and “red-tide” shellfish 4 
poisoning (Gillespie et al., 1986; Nakanishi, 1985; Swift and Swift, 1993). The 5 
causative cyclic polyether toxins, the ciguatoxins (CTX) and brevetoxins (PbTx), are 6 
produced by dinoflagellates of the Gambierdiscus and Karenia families, respectively 7 
(Bidard et al., 1984). The pharmacological effects of these site 5 toxins on NaV 8 
channels are diverse and include hyperpolarising shifts in activation, a decrease in 9 
peak current, as well as effects on the voltage-dependence and time course of channel 10 
inactivation (Inserra et al., 2017; Lombet et al., 1987; Trainer et al., 1994). Critical 11 
residues for site 5 binding are less well defined, although photoaffinity labelling 12 
studies with PbTx highlight DI S6 and most of the DIV S5-S6 linker, including the 13 
pore loop with the residues that form part of the sodium selectivity filter (Figure 4 14 
and 14) (Trainer et al., 1994). 15 
 16 
PbTx’s are classified as either A or B depending on their backbone structure. The 17 
extensively studied PbTx-3 shifted the voltage-dependence of activation of 18 
tetrodotoxin-sensitive channels expressed in nodose ganglia (Jeglitsch et al., 1998), 19 
inhibited NaV channel inactivation, and increased channel opening time in single 20 
channel recordings (Purkerson et al., 1999). Although PbTx-3 showed some 21 
selectivity for the skeletal muscle isoform (NaV1.4) over the cardiac (NaV1.5) and rat 22 
brain (NaV1.2) isoforms in a sodium dependent cytotoxicity assays (Bottein 23 
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Dechraoui and Ramsdell, 2003), selectivity across the full panel of NaV channels is 1 
unknown, and selectivity of other PbTxs has thus far not been studied.   2 
 3 
The ciguatoxins are NaV channel activator toxins that accumulate in fish through the 4 
marine food chain and cause the seafood disease ciguatera in humans. Of the several 5 
structurally related congeners, denoted as Pacific, Indian and Caribbean ciguatoxins 6 
depending on their origin, P-CTX-1 (Pacific ciguatoxin 1) is the most potent, and the 7 
isoform responsible for most symptoms in the Pacific (Lewis, 2006). Although 8 
differential effects on tetrodotoxin-resistant and -sensitive isoforms expressed in 9 
sensory neurons – including shifts in the voltage-dependence of activation, a decrease 10 
in peak current, and effects on recovery from inactivation – were reported several 11 
years ago, the relative NaV channel subtype selectivity of P-CTX-1 has remained 12 
unexplored until relatively recently (Strachan et al., 1999). In SH-SY5Y cells, P-13 
CTX-1-induced effects were mediated predominantly through NaV1.3 (Vetter et al., 14 
2012b), consistent with the induction of a small persistent current at this, but not 15 
other, NaV channel isoforms (Inserra et al., 2017). While P-CTX-1 is relatively non-16 
selective for NaV1.1-NaV1.9 overall, as evidenced by a shift in the voltage-17 
dependence of activation at all isoforms, effects on fast inactivation only occurred at 18 
NaV1.2, NaV1.3 and NaV1.9.   19 
 20 
Antillatoxin is a NaV channel activator isolated from the cyanobacteria Lyngbya 21 
majuscula (Orjala et al., 1995) and causes Na+ influx via rNaV1.2, 1.4 and 1.5 (Cao et 22 
al., 2010). Additionally, antillatoxin causes changes in membrane potential resulting 23 
from hNaV1.7 activation (Zhao et al., 2016).  While there is evidence for allosteric 24 
coupling with site 2 and 5, the exact binding site remains unspecified (Cao et al., 25 
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2010; Li et al., 2001). Interestingly, most studies assessing the pharmacology of 1 
antillatoxin were conducted using fluorescence-based assays, and electrophysiological 2 
characterization of its effects on NaV channel gating, particularly at different isoforms, 3 
is sparse. 4 
 5 
5. NaV channel activators as tool compounds 6 
 7 
5.1. NaV channel assays 8 
NaV channels are key therapeutic targets for pain, epilepsy and cardiac arrhythmias; 9 
therefore several high-throughput assays have been developed to screen and profile 10 
the activity of NaV channel modulators, including fluorescence-based assays and 11 
automated patch-clamp electrophysiology (Dunlop et al., 2008; Yu et al., 2016). 12 
Fluorescence-based assays provide an indirect measure of NaV channel function by 13 
detecting changes in membrane potential or intracellular sodium ion concentration, 14 
with several fluorescent dyes commercially available (Yu et al., 2016).  Whilst the 15 
results from fluorescence-based assays do not always correlate well with patch-clamp 16 
electrophysiology, which remains the standard for measuring NaV channel function, 17 
they are comparatively cheaper, higher throughput, and do not require significant 18 
expertise to perform (Dunlop et al., 2008; Yu et al., 2016).  19 
To activate NaV channels in fluorescence-based assays, the alkaloid veratridine or the 20 
pyrethroid deltamethrin are commonly used. Veratridine induces a robust fluorescent 21 
response with membrane potential dyes in cells heterologously expressing NaV1.1-22 
1.7, but has negligible effects on NaV1.8 (Deuis et al., 2015; Vickery et al., 2004). In 23 
contrast, deltamethrin has a limited effect on the membrane potential of cells 24 
heterologously expressing TTXs NaV channels, but causes a robust fluorescent 25 
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response in cells heterologously expressing NaV1.8 (Deuis et al., 2016a; Vickery et 1 
al., 2004). As NaV channel activators used in fluorescence-based assays likely 2 
stabilise different channel conformations, it is unclear if these assays exhibit bias 3 
towards detection of NaV channel modulators with a specific mechanism of action 4 
and/or binding site.  5 
 6 
5.2. NaV channel target engagement in vivo 7 
A key step in the development of any pharmaceutical is to demonstrate target 8 
engagement and efficacy in vivo. For analgesics, assessment of target-engagement in 9 
vivo is challenging, as most commonly used pre-clinical rodent models of pain, which 10 
are based on quantification of pain responses induced by local injection of formalin, 11 
carrageenan or Complete Freund’s Adjuvant, have a multifactorial pathophysiology. 12 
Demonstrating target engagement in vivo ensures a sufficient concentration of an 13 
analgesic is reached at the site of the intended target, providing crucial information to 14 
guide dosing for in vivo efficacy studies.  15 
NaV1.7 is of particular interest as an analgesic target because loss-of-function 16 
mutations in SCN9A, the gene encoding NaV1.7, is a cause of congenital insensitivity 17 
to pain, an extremely rare condition resulting in the inability to sense pain (Cox et al., 18 
2006; Goldberg et al., 2007). Therefore, selective pharmacological inhibitors of 19 
NaV1.7 are being actively pursued as novel analgesics (Sun et al., 2014). The 20 
importance of NaV channels in the initiation and propagation of action potentials in 21 
nociceptive sensory neurons is undisputed, with local injection of non-selective NaV 22 
channel activators such as veratridine, ciguatoxin, grayanotoxin and aconitine causing 23 
spontaneous pain behaviours in mice, rats and humans (Focken et al., 2016; Gingras 24 
et al., 2014; Vetter et al., 2012b). These effects in turn can be reversed by NaV 25 
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channel inhibitors, providing convenient in vivo target engagement models. For 1 
example, reversal of pain behaviours induced by local injection of aconitine was used 2 
to demonstrate in vivo target engagement of an aryl sulfonamide class of small 3 
molecules with NaV1.7 activity (Focken et al., 2016; Gingras et al., 2014). Given that 4 
activation of other NaV channel isoforms, including NaV1.1 or NaV1.6, is sufficient to 5 
elicit pain behaviours in rodents (Deuis et al., 2013; Osteen et al., 2016), the 6 
usefulness of this approach is particularly apparent for highly subtype-selective NaV 7 
channel activators. Recently, a NaV1.7-specific target-engagement model was 8 
developed based on intraplantar injection of the selective NaV1.7 activator OD1 9 
(Deuis et al., 2016b). Similar to behaviours elicited by non-selective NaV channel 10 
activators, local administration of OD1 in mice causes rapid development of pain 11 
behaviours, including flinching and licking of the injected hind paw. Consistent with 12 
the high NaV1.7-selectivity of OD1, these behaviours were significantly attenuated in 13 
NaV1.7-/- mice and by administration of selective NaV1.7 inhibitors GpTx-1 and PF-14 
04856264 (Deuis et al., 2016b). OD1 is therefore a useful pharmacological tool to 15 
rapidly profile on-target activity of NaV1.7 inhibitors at sensory nerve endings in vivo. 16 
 17 
5.3. Elucidating pain pathways  18 
Five NaV channel subtypes (NaV1.1, 1.6, 1.7, 1.8, 1.9) are expressed on adult 19 
peripheral sensory neurons (Black et al., 1996; Fukuoka et al., 2008; Fukuoka and 20 
Noguchi, 2011). Due to a lack of subtype selective NaV channel inhibitors, 21 
determining the role of NaV channels in pain pathways has heavily relied on the 22 
knockout of NaV channel genes in mice. While this approach has been partially 23 
successful for NaV1.7, NaV1.8 and NaV1.9, global knockout of NaV1.1 and NaV1.6 is 24 
lethal as these isoforms are expressed in the central nervous system and NaV1.6 on the 25 
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nodes of Ranvier in motor neurons (Caldwell et al., 2000; Gingras et al., 2014; Leo et 1 
al., 2010; Meisler et al., 2001; Whitaker et al., 2001; Yu et al., 2006). Instead, the role 2 
of NaV1.1 and NaV1.6 in specific pain pathways has been elucidated using selective 3 
NaV channel activator toxins. 4 
Intraplantar injection of δ-theraphotoxin-Hm1a (5 µM), a selective NaV1.1 activator 5 
with low nM EC50 (38 nM), causes spontaneous pain behaviours and mechanical 6 
allodynia in mice, suggesting a role for NaV1.1 in mechanical pain (Osteen et al., 7 
2016). However, at higher concentrations (>100 nM) Hm1a also inhibits KV channels, 8 
including KV2.1, KV2.2, KV4.1, KV4.2 and KV4.3 (Escoubas et al., 2002). KV2.1 is a 9 
delayed rectifier channel that when open, causes outward current of potassium ions, 10 
allowing the cell membrane to repolarize after an action potential. It is expressed on 11 
peripheral sensory neurons and is important in the regulation of neuronal excitability; 12 
therefore, off-target activity at KV2.1 could contribute to spontaneous pain behaviours 13 
observed after intraplantar injection of high concentrations of Hm1a (Kim et al., 2002; 14 
Tsantoulas et al., 2014). While Hm1a-induced spontaneous pain and mechanical 15 
allodynia was partially attenuated in conditional NaV1.1 knockout mice, basal 16 
mechanical sensitivity of this mouse line was not reported (Osteen et al., 2016). 17 
Therefore, further studies are required to confirm the role of NaV1.1 in mechanical 18 
pain and other pain modalities.  19 
In peripheral sensory neurons, NaV1.6 is predominately expressed on the nodes of 20 
Ranvier, suggesting that it is crucial for the propagation of action potentials in 21 
myelinated fibers (Caldwell et al., 2000; Fukuoka et al., 2008). Indeed, intraplantar 22 
injection of the β-scorpion Cn2 (1-30 nM), a selective activator of NaV1.6 (EC50 39 23 
nM), causes spontaneous pain behaviours, mechanical allodynia and enhances 4-24 
aminopyridine-induced cold allodynia in mice (Deuis et al., 2013). A role for NaV1.6-25 
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expressing neurons in pathological cold pain was later confirmed using a combination 1 
of NaV channel knockout mice lines and selective NaV channel inhibitors in mouse 2 
models of oxaliplatin- and ciguatoxin- induced cold allodynia (Deuis et al., 2013; 3 
Minett et al., 2014; Vetter et al., 2012b; Zimmermann et al., 2013). While NaV1.6 is 4 
predominately expressed on A-fibres, it also expressed at comparatively low levels in 5 
C-fibers, where its role is unknown (Fukuoka et al., 2008).  6 
 7 
5.4.  Drug Leads 8 
NaV channel activator toxins may provide useful drug leads for the treatment of 9 
conditions caused by loss of NaV channel function. For example, selective NaV1.1 10 
activators might find application as treatment for specific types of epilepsy, such as 11 
Dravet syndrome, which is associated with heterozygous loss-of-function mutations in 12 
SCN1A, the gene encoding NaV1.1 (Claes et al., 2001). Dravet syndrome is 13 
characterized by severe seizures that begin during infancy, followed by cognitive 14 
impairment, behavioural disorders and motor deficits that develop during early 15 
childhood. Potential therapeutics for Dravet syndrome would require exquisite 16 
selectivity for NaV1.1 over the other NaV subtypes, as non-selective activation of NaV 17 
channels would result in a limited therapeutic window, with high risk of seizures, 18 
cardiac arrhythmias and death. However, given the poor prognosis and limited 19 
available treatments for Dravet syndrome, delivery of a NaV1.1 activator by an 20 
intrathecal pump that limits systemic exposure is a feasible option to improve the 21 
therapeutic window. Although less well-validated, NaV1.4 or NaV1.5 activators might 22 
hypothetically treat conditions such as congenital myasthenic syndrome, which is 23 
associated with severe muscle weakness; or cardiac arrhythmias and insufficiencies 24 
(Jurkat-Rott et al., 2010; Zimmer et al., 2014).  25 
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6. Conclusions 1 
NaV channel activators, produced by bacteria, dinoflagellates, algae and many 2 
venomous animals including scorpions, sea anemone, wasps, spiders, cone snails and 3 
snakes, are a structurally and functionally diverse group of compounds that interact 4 
with multiple sites on NaV channels to enhance function. In practice, the effects 5 
elicited by NaV channel activators are as diverse as their origins, and include 6 
enhanced activation, decreased inhibition or altered conductance. However, it is 7 
becoming increasingly clear that this remains a simplified view of the pharmacology 8 
of NaV channel activators. For example, enhanced activation can include effects on 9 
the voltage-dependence of activation or changes in channel opening kinetics. 10 
Similarly, effects on inactivation can manifest as altered voltage- or time-dependence 11 
of inactivation; effects on fast or slow inactivation; altered recovery from inactivation, 12 
incomplete inactivation or emergence of resurgent or leak currents. Moreover, the 13 
assumption that biophysical effects on channel gating are similar across different 14 
isoforms clearly does not hold true. In combination with different binding affinities 15 
for individual isoforms, we are just beginning to understand the pharmacological 16 
complexity of NaV channel activators. Accordingly, systematic pharmacological 17 
characterization of these compounds, in light of better molecular tools and improved 18 
crystal structures available to us now and in future, will undoubtedly provide 19 
additional insight into the therapeutic and practical applications for NaV channel 20 
activators. 21 
 22 
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Table 1. Potency and selectivity of NaV activator toxins at NaV1.1-1.9. Where 
available the EC50 values are provided. If not available activity is classified as either 
sensitive (S) or insensitive (IS) at the concentration stated.  
Toxin 
N
a V
1.
1 
N
a V
1.
2 
N
a V
1.
3 
N
a V
1.
4 
N
a V
1.
5 
N
a V
1.
6 
N
a V
1.
7 
N
a V
1.
8 
N
a V
1.
9 
R
ef
 
Alkaloid 
Batrachotoxin NA S  
(10 
µM) 
S  
(10 
µM) 
S  
(10 
µM) 
S  
(10 
µM) 
S  
(10 
µM) 
S  
(10 
µM) 
S  
(10 
µM) 
NA (Bos
man
s et 
al., 
2004
; Li 
et 
al., 
2002
; 
Log
an et 
al., 
2016
) 
Spider 
δ-hexatoxin-
Mg1a 
S (5 
µM) 
S (5 
µM) 
S (5 
µM) 
IS (5 
µM) 
IS (5 
µM) 
S (5 
µM) 
S (5 
µM) 
IS (5 
µM) 
 (Ya
maji 
et 
al., 
2009
) 
δ-theraphotoxin-
Cg3a 
NA NA 2 µM > 5 µM 125 nM NA > 5 µM NA NA (Hua
ng et 
al., 
2015
) 
δ-theraphotoxin-
Cg1a 
NA 870 nM 845 nM 339 nM 335 nM NA 348 nM NA NA (Tao 
et 
al., 
2016
) 
δ-theraphotoxin-
Hm1a 
38 nM 236 nM 220 nM IS (100 
nM) 
IS (100 
nM) 
IS (100 
nM) 
IS (100 
nM) 
IS (100 
nM) 
IS (100 
nM) 
(Ost
een 
et 
al., 
2016
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) 
Wasp 
β-pompilidotoxin S (46 
µM) 
21 µM S (46 
µM) 
IS (140 
nM) 
IS (140 
nM) 
30 µM S (46 
µM) 
NA NA (Sch
iavo
n et 
al., 
2010
) 
α-Scorpion 
OD1 NA 5 µM 3 µM 10 nM 4 µM 47 nM 7 nM IS (1 
µM) 
NA (Dur
ek et 
al., 
2013
b; 
Mae
rtens 
et 
al., 
2006
a) 
Ts2 NA S (1 
µM) 
S (1 
µM) 
IS (1 
µM) 
S (1 
µM) 
S (1 
µM) 
S (1 
µM) 
IS (1 
µM) 
NA (Col
ogna 
et 
al., 
2012
) 
MeuNaTxα-1 NA S (1 
µM) 
S (1 
µM) 
IS (1 
µM) 
IS (1 
µM) 
3 µM S (1 
µM) 
IS (1 
µM) 
NA (Zhu 
et 
al., 
2012
) 
MeuNaTxα-2 NA IS (1 
µM) 
IS (1 
µM) 
2 µM IS (1 
µM) 
IS (1 
µM) 
IS (1 
µM) 
IS (1 
µM) 
NA (Zhu 
et 
al., 
2012
) 
MeuNaTxα-5 NA IS (2 
µM) 
S (2 
µM) 
S (2 
µM) 
S (2 
µM) 
0.79 
µM 
S (2 
µM) 
IS (2 
µM) 
NA (Zhu 
et 
al., 
2012
) 
MeuNaTxα-12 0.91 
µM 
S (10 
µM) 
NA S (10 
µM) 
IS (10 
µM) 
S (10 
µM) 
NA NA NA (Zhu 
et 
al., 
2013
) 
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MeuNaTxα-13 2.5 µM S (10 
µM) 
NA S (10 
µM) 
IS (10 
µM) 
S (10 
µM) 
NA NA NA (Zhu 
et 
al., 
2013
) 
β-Scorpion 
Cn2 IS (300 
nM) 
IS (300 
nM) 
IS (300 
nM) 
IS (300 
nM) 
IS (300 
nM) 
40 nM IS (300 
nM) 
NA NA (Sch
iavo
n et 
al., 
2006
) 
Tz1 NA S (10 
µM) 
NA IS (10 
µM) 
IS (10 
µM) 
S (10 
µM) 
IS (10 
µM) 
NA NA (Lei
pold 
et 
al., 
2006
) 
Tf2 IS (1 
µM) 
IS (1 
µM) 
S (1 
µM) 
IS (1 
µM) 
IS (1 
µM) 
IS (1 
µM) 
IS (1 
µM) 
IS (1 
µM) 
NA (Ca
mar
gos 
et 
al., 
2015
) 
Ts1 IS (100 
nM) 
IS (100 
nM) 
S (100 
nM) 
S (100 
nM) 
S (100 
nM) 
S (100 
nM) 
IS  (100 
nM) 
IS  (100 
nM) 
NA (Pei
gneu
r et 
al., 
2015
b) 
Cone snail 
δ-SuVIA NA NA 4 nM 5 nM 1 nM  2.5 nM NA NA NA (Jin 
et 
al., 
2015
) 
ι-RXIA IS (50 
µM) 
18 µM IS (50 
µM) 
IS (50 
µM) 
IS (50 
µM) 
1.8 µM S (50 
µM) 
IS (50 
µM) 
IS (50 
µM) 
(Fie
dler 
et 
al., 
2008
) 
Sea anemone            
ATX-II 6 nM 8 nM 759 nM 109 nM 49 nM ~180 
nM 
1.8 µM NA NA (Oli
veira 
et 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 83
al., 
2004
; 
Wan
ke et 
al., 
2009
) 
AFT-II 391 nM 2 µM 459 nM 31 nM 63 nM ~300 
nM 
5.8 µM NA NA (Oli
veira 
et 
al., 
2004
; 
Wan
ke et 
al., 
2009
) 
Bc-III ~300 
nM 
1.5 µM 1.5 µM 821 nM 307 nM ~900 
nM 
5.7 µM NA NA (Oli
veira 
et 
al., 
2004
; 
Wan
ke et 
al., 
2009
) 
CGTX-II 165 nM > 1 µM > 1 µM > 1 µM 105 nM 133 nM IS (50 
nM) 
NA NA (Zah
aren
ko et 
al., 
2012
) 
Dinoflagellate 
P-CTX-1 8 nM 8 nM 3 nM 18 nM 10 nM 18 nM 13 nM 2 nM S (1 
nM) 
(Inse
rra 
et 
al., 
2017
) 
NA – not assessed 
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Table 2. Summary of experimentally determined NaV channel interactions with NaV activator toxins. For simplicity, only the S1-S2 and S3-S4 
linkers or the S5 and S6 transmembrane segments (or S5-S6 linker as indicated) are presented for DI, DII, DIII and DIV. The type of 
experimental evidenced is abbreviated as follows: single-point channel mutations (S); chimeric channels (C); competitive radioligand binding 
(R); photoaffinity labelling (P). White shading indicates an experimental determined interaction, light grey shading indicates the interaction is 
unknown, and dark grey shading indicates that it has been experimentally determined that there is no interaction. 
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 DI DII DIII DIV 
R
e
f
 
 S1–S2 S3–S4 S5 S6 S1–S2 S3–S4 S5 S6 S1–S2 S3–S4 S5 S6 S1–S2 S3–S4 S5 S6 
Alkaloids 
Batrachotoxin    S    S    S    S (Toma et 
al., 2016; 
Wang et 
al., 2001; 
Wang et 
al., 2000b; 
Wang and 
Wang, 
1998, 
1999) 
Grayanotoxin    S            S (Ishii et 
al., 1999; 
Kimura et 
al., 2000) 
Veratridine    S            S (Wang et 
al., 2000a) 
Spider 
δ-hexatoxin-Ar1a   R*L         R* R*   (Little et 
al., 1998) 
δ-hexatoxin-Hv1a   R*L         R* R*   (Little et 
al., 1998) 
β-hexatoxin-Mg1a   R#L R# R#     R#L  R*   (Corzo et 
al., 2003) 
δ-theraphotoxin-
Cg1a 
             S   (Tao et al., 
2016) 
δ-theraphotoxin-              S   (Huang et 
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Cg3a al., 2015) 
δ-theraphotoxin-
Hm1a 
 C    C    C   C C   (Osteen et 
al., 2016) 
Wasp 
β-pompilidotoxin C C CL C C CL C C C C S CL (Kinoshita 
et al., 
2001) 
α-Scorpion 
LqTx              S   (Rogers et 
al., 1996) 
LqhII   SL         S S   (Leipold et 
al., 2005; 
Leipold et 
al., 2004; 
Wang et 
al., 2011) 
LqhIII              S   (Leipold et 
al., 2005; 
Leipold et 
al., 2004) 
β-Scorpion 
CssIV C  CL S S CL C C SL C C CL (Cestele et 
al., 1998; 
Cestele et 
al., 2006; 
Zhang et 
al., 2011) 
Tz1 C C CL  S     SL C C CL (Leipold et 
al., 2006) 
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*Competitive radioligand binding with LqhII 
#Competitive radioligand binding with CssIV 
$Competitive radioligand binding with brevetoxin 
LS5–S6 linker
Cone snail 
δ-SVIE              S   (Leipold et 
al., 2005) 
Sea anemone 
ATX-II              S   (Rogers et 
al., 1996) 
ApB              S   (Benzinge
r et al., 
1998) 
Dinoflagellate 
Brevetoxin    P           PL (Trainer et 
al., 1994) 
Ciguatoxin    R$           R$L (Lombet et 
al., 1987) 
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Figure legends 1 
Figure 1. General structural topology of NaV channels. a) NaV channels consist of 2 
four homologous domains (domain I, II, III and IV) that are linked via large 3 
intracellular loops. Each domain contains 6 transmembrane segments (S1 - S6) which 4 
can be functionally divided into the voltage-sensing domains (VSD; segments S1-S4) 5 
and the pore domains (PD, segments S5-S6). The S4 segments carry several highly 6 
conserved positively charged arginine and lysine residues (gating charges) which 7 
move across the cell membrane upon changes in the membrane potential and thus 8 
function as the voltage sensors of the channel. b) Top view of the NaV channel. The 9 
ion-conducting pore of the channel is formed by the four assembled PDs of DI - DIV, 10 
which are each shaped by segments S5 and S6 plus their extracellular linker. The 11 
arrangement of the voltage-sensing (S1-S4) and pore-forming (S5-S6) segments are 12 
offset so that in functional channels, the voltage sensor of each domain is closest to 13 
the pore-forming segment of the following domain. Broken lines indicate intracellular 14 
linkers and loops; continuous lines indicate extracellular linkers. 15 
 16 
Figure 2. Simplified gating model of NaV channels. NaV channels exist in at least 17 
three, and likely many more, distinct states: resting (closed), open, and inactivated. In 18 
the resting or closed state of NaV channels, all four VSD are presumably in the 19 
inactivated state. Movement of the DI-DIII VSDs, which is subsequently transferred 20 
to the PDs via the S4 - S5 linkers, changes channel conformation and allows the pore 21 
to become permeable to sodium ions. Channel inactivation requires movement of the 22 
domain IV VSD, which brings the IFM motif on the third intracellular loop between 23 
DIII and DIV close to the intracellular opening of the pore and thus inactivates it. 24 
 25 
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Figure 3. Simplified classification of NaV channel modulators 1 
In a simple approach, the binding sites of NaV channel modulators can be divided into 2 
the pore region (consisting of all four S5 and S6 segments including their linkers) and 3 
the four voltage-sensing domains (consisting of segments S1 to S4 including their 4 
extracellular linkers). Further functional classification of activators and inhibitors 5 
results in four possible classes of NaV channel modulators for each binding site. Some 6 
NaV channel modulators belong to more than one class and can have differential 7 
functional effects on distinct channel isoforms. Given that binding to the VSDs of 8 
different domains likely preferentially affects distinct channel functions, the number 9 
of possible classes of NaV modulators may be even greater. 10 
 11 
Figure 4. Amino acid sequence alignment of human NaV isoforms for DI S6 12 
Multiple amino acid sequence alignment of domain I segment 6 and adjacent residues 13 
of hNaV α-subunit isoforms was performed using Clustal Omega 1.2.2 with default 14 
parameters. We used the amino acid sequences in the canonical isoform 1 as provided 15 
by the UniProtKB database (http:// www.uniprot.org/). UniProtKB entry identifiers: 16 
P35498 (SCN1A, hNaV1.1); Q99250 (SCN2A, hNaV1.2); Q9NY46 (SCN3A, 17 
hNaV1.3); P35499 (SCN4A, hNaV1.4); Q14524 (SCN5A, hNaV1.5); Q9UQD0 18 
(SCN8A, hNaV1.6); Q15858 (SCN9A, hNaV1.7); Q9Y5Y9 (SCN10A, hNaV1.8); 19 
Q9UI33 (SCN11A, hNaV1.9). The definition of transmembrane segments and intra- 20 
and extracellular domains are as specified by the UniProtKB database. Where dots are 21 
shown instead of letters in NaV isoform sequences, the amino acid is identical to the 22 
one in NaV1.1. Consensus symbols: * = positions which have a single, fully conserved 23 
residue in all sequences; : = conservation between groups of strongly similar 24 
properties in all sequences (STA; NEQK; NHQK; NDEQ; QHRK; MILV; MILF; 25 
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HY; FYW); . = conservation between groups of weakly similar properties in all 1 
sequences (CSA; ATV; SAG; STNK; STPA; SGND; SNDEQK; NDEQHK; 2 
NEQHRK; FVLIM; HFY). Amino acid residues important for NaV channel activator 3 
toxin binding are in bold. Residues are additionally circled if evidence is based on 4 
channel mutagenesis studies and sequence parts are highlighted in rectangles if 5 
evidence is based on studies with chimeric channels. As several studies have been 6 
carried out on rat NaV channels, the results are only indicated if the human isoform 7 
has the same residues at the corresponding positions. Brevetoxin, ciguatoxin, 8 
batrachotoxin, grayanotoxin and veratridine have been shown to bind to residues in 9 
the DI S6 region. 10 
 11 
Figure 5. Amino acid sequence alignment of human NaV isoforms for DII S6 12 
Multiple sequence alignment of domain II segment 6 and adjacent residues was 13 
performed as stated in Figure 4. Batrachotoxin binds to residues in DII S6. 14 
 15 
Figure 6. Amino acid sequence alignment of human NaV isoforms for DIII S5 - 16 
S6 linker 17 
Multiple sequence alignment of domain II S5 - S6 linker and adjacent residues was 18 
performed as stated in Figure 4. The shaded conserved lysine and aspartic acid 19 
residues are part of the channels sodium selectivity filter in the P-loop of DIII. This 20 
linker contains residues important for interactions with batrachotoxin as well as the β-21 
scorpion toxins CssIV and Tz1. 22 
 23 
Figure 7. Amino acid sequence alignment of human NaV isoforms for DIII S6 24 
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Multiple sequence alignment of domain III segment 6 and adjacent residues was 1 
performed as stated in Figure 4. This segment contains important residues for 2 
batrachotoxin binding. 3 
 4 
Figure 8. Amino acid sequence alignment of human NaV isoforms for DIV S6 5 
Multiple sequence alignment of domain IV segment 6 and adjacent residues was 6 
performed as stated in Figure 4. DIV S6 contains residues that are important for 7 
batrachotoxin and veratridine binding. 8 
 9 
Figure 9. Amino acid sequence alignment of human NaV isoforms for DIV VSD 10 
S3-S4 linker 11 
Multiple sequence alignment of domain IV S3 - S4 linker and adjacent residues was 12 
performed as stated in Figure 4. The shown region contains important residues for 13 
interactions with the δ-spider toxins Cg1a, Cg3a and Hm1a β-pompilidotoxin, the α-14 
scorpion toxins LqTx, LqhII and LqhIII, the δ-conotoxin SVIE, and the sea anemone 15 
toxins ATX-II and ApB. 16 
 17 
Figure 10. Amino acid sequence alignment of human NaV isoforms for DIV S1 – 18 
S2 linker 19 
Multiple sequence alignment of domain IV S1 – S2 linker and adjacent residues was 20 
performed as stated in Figure 4. The DIV S1 – S2 linker contains important residues 21 
for LqhII and Hm1a binding. 22 
 23 
Figure 11. Amino acid sequence alignment of human NaV isoforms for DI S5 – S6 24 
linker 25 
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Multiple sequence alignment of part of the domain I S5 - S6 linker was performed as 1 
stated in Figure 4. The vertical lines indicate a break in the sequence. This region 2 
contains important residues for CssIV and LqhII binding. 3 
 4 
Figure 12. Amino acid sequence alignment of human NaV isoforms for DII S1 – 5 
S2 linker 6 
Multiple sequence alignment of domain II S1 – S2 linker and adjacent residues was 7 
performed as stated in Figure 4. The DII S1 – S2 linker contains a proline important 8 
for CssIV binding. 9 
 10 
Figure 13. Amino acid sequence alignment of human NaV isoforms for DII S3 – 11 
S4 linker 12 
Multiple sequence alignment of domain II S3 – S4 linker and adjacent residues was 13 
performed as stated in Figure 4. The DII S3 – S4 linker contains important residues 14 
for CssIV and Tz1 binding. 15 
 16 
Figure 14. Amino acid sequence alignment of human NaV isoforms for DIV S5 –17 
S6 linker 18 
Multiple sequence alignment of part of the domain IV S5 – S6 linker was performed 19 
as stated in Figure 4. The shaded conserved alanine and aspartic acid residues are part 20 
of the channels sodium selectivity filter in the P-loop of DIV. This region contains 21 
important residues for interactions with brevetoxin and ciguatoxin. 22 
 23 
 24 
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Highlights 
• Voltage-gated sodium channel activator toxins occur in many venoms 
• Sodium channel activators are important tool compounds and drug leads 
• These compounds modulate voltage-gated sodium channels with high selectivity 
 
